Racine-Poon A - Search Results

1

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis.

Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W. Racine-Poon A, et al. Clin Pharmacol Ther. 1997 Dec;62(6):675-90. doi: 10.1016/S0009-9236(97)90087-4. Clin Pharmacol Ther. 1997. PMID: 9433396 Clinical Trial.

2

Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.

Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Müller P, et al. Eur J Clin Pharmacol. 1994;47(3):231-45. doi: 10.1007/BF02570503. Eur J Clin Pharmacol. 1994. PMID: 7867676 Clinical Trial.

3

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A; IRIS Study Group. Schmidli H, et al. Among authors: racine poon a. Br J Clin Pharmacol. 2005 Jul;60(1):35-44. doi: 10.1111/j.1365-2125.2005.02372.x. Br J Clin Pharmacol. 2005. PMID: 15963092 Free PMC article. Clinical Trial.

4

An interaction study with cimetidine and the new angiotensin II antagonist valsartan.

Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. Schmidt EK, et al. Eur J Clin Pharmacol. 1998 Feb;53(6):451-8. doi: 10.1007/s002280050406. Eur J Clin Pharmacol. 1998. PMID: 9551704 Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Peng B, et al. Among authors: racine poon a. J Clin Oncol. 2004 Mar 1;22(5):935-42. doi: 10.1200/JCO.2004.03.050. J Clin Oncol. 2004. PMID: 14990650 Clinical Trial.

6

Statistical methods for population pharmacokinetic modelling.

Racine-Poon A, Wakefield J. Racine-Poon A, et al. Stat Methods Med Res. 1998 Mar;7(1):63-84. doi: 10.1177/096228029800700106. Stat Methods Med Res. 1998. PMID: 9533262 Clinical Trial.

7

Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.

Schmidli H, Bretz F, Racine-Poon A. Schmidli H, et al. Among authors: racine poon a. Stat Med. 2007 Nov 30;26(27):4925-38. doi: 10.1002/sim.2957. Stat Med. 2007. PMID: 17590875

8

A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.

Pozzi L, Schmidli H, Gasparini M, Racine-Poon A. Pozzi L, et al. Among authors: racine poon a. Stat Med. 2013 Dec 10;32(28):5008-27. doi: 10.1002/sim.5932. Epub 2013 Sep 11. Stat Med. 2013. PMID: 24022748

9

Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.

Racine-Poon A, Moppert J. Racine-Poon A, et al. Br J Clin Pharmacol. 1985;19 Suppl 2(Suppl 2):143S-149S. doi: 10.1111/j.1365-2125.1985.tb02755.x. Br J Clin Pharmacol. 1985. PMID: 4005116 Free PMC article.

10

An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

Wakefield J, Racine-Poon A. Wakefield J, et al. Stat Med. 1995 May 15-30;14(9-10):971-86. doi: 10.1002/sim.4780140917. Stat Med. 1995. PMID: 7569514 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters